Medtronic Diabetes announces world's first approval for MiniMed™ 780G System with Simplera Sync™ disposable, all-in-one sensor

Rhea-AI Summary

Medtronic plc (MDT) receives CE Mark approval for the MiniMed™ 780G system with Simplera Sync™ sensor, offering improved user experience and half the size of previous sensors. The system automatically adjusts glucose levels and features a Meal Detection™ feature to reduce post-meal hyperglycemia. The system is also compatible with the world's only 7-day infusion set and requires no fingersticks.

Insights

Medical Research Analyst

The CE Mark approval of Medtronic's MiniMed™ 780G system with Simplera Sync™ sensor represents a significant advancement in diabetes management technology. This new sensor improves the user experience through a simplified insertion process and reduced size, which is likely to enhance patient compliance and comfort. The MiniMed™ 780G system stands out with its Meal Detection™ feature and a 'treat to target' approach that aims to mimic non-diabetic glucose levels, potentially improving patient outcomes.

From a research perspective, the system's ability to adjust insulin delivery automatically and the provision of a lower glucose target setting align with the current trend towards more personalized and adaptive diabetes care. The reported Time in Range of nearly 80% is noteworthy, as it surpasses the commonly accepted threshold for well-managed diabetes, which is particularly relevant given the diverse user base across various geographies and cultures. The system's compatibility with both iOS and Android devices further enhances its accessibility and integration into patients' daily lives.

Market Research Analyst

The European launch of the MiniMed™ 780G system with the new Simplera Sync™ sensor could potentially strengthen Medtronic's position in the diabetes care market. The ease of use and improved patient experience are critical factors in product adoption and market penetration. As the system is already the most widely used automated insulin delivery system in Europe since its initial launch in 2020, this innovation may reinforce customer loyalty and attract new users seeking advanced diabetes management solutions.

Medtronic's phased commercial launch strategy allows for controlled market entry and feedback collection, which could inform further product development and marketing efforts. The lack of FDA approval in the U.S. for the Simplera Sync™ sensor indicates a future growth opportunity once regulatory hurdles are cleared. Investors should monitor the adoption rates post-launch and any developments regarding U.S. approval, as these will be key indicators of the system's commercial success and impact on Medtronic's financial performance.

Healthcare Economist

The economic implications of the MiniMed™ 780G system's CE Mark approval extend beyond the direct financial performance of Medtronic. The system's advanced features, such as the Meal Detection™ and automated insulin adjustments, may contribute to reduced long-term healthcare costs associated with diabetes complications. By potentially improving glycemic control and reducing episodes of hyperglycemia, there could be a decrease in the incidence of costly diabetes-related complications, such as retinopathy or kidney disease.

Moreover, the system's ability to maintain high Time in Range percentages is indicative of its efficacy in diabetes management, which could lead to lower dependency on healthcare services and resources. This has the potential to alleviate the economic burden on healthcare systems, especially in countries where diabetes prevalence is high. The economic benefits, however, must be weighed against the initial costs of adopting such advanced technology and the long-term cost-effectiveness should be assessed through real-world data and health economic studies.

With CE Mark approval, the benefits of the MiniMed™ 780G system are now available with a new sensor that takes less than 10 seconds to insert¹

DUBLIN, Jan. 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for the MiniMed™ 780G system with Simplera Sync™, a disposable, all-in-one continuous glucose monitor (CGM) requiring no fingersticks or overtape. Simplera Sync™ features an improved user experience with a simple, two-step insertion process and is half the size of previous Medtronic sensors.*  

The MiniMed 780G system with Simplera Sync™ sensor will be available in Europe via limited release in spring 2024. Medtronic will begin the phased commercial launch in Europe in the summer of 2024. Today, the MiniMed™ 780G system can be used with the Guardian™ 4 sensor.

The MiniMed™ 780G system is Medtronic's most advanced insulin delivery system, automatically adjusting and correcting^† glucose levels every 5 minutes.^§ It's the world's only system with a Meal Detection™ feature^‡ that is designed to reduce post-meal hyperglycemia when users occasionally forget to give themselves insulin or underestimate the number of carbs in their snacks or meal. The system, which is available with the world's only 7-day infusion set, also features one of the lowest glucose target settings (as low as 100 mg/dL) of any automated insulin delivery system. With this "treat to target" approach, the system more closely mirrors the glucose levels of someone not living with diabetes. With both Simplera Sync™ sensor and the Guardian™ 4 sensor, no fingersticks are required.**

"A challenging aspect of living with diabetes is counting carbohydrates and dosing the right amount of insulin before consuming snacks and meals. Many people underestimate their carbs, which can lead to high blood sugars (hyperglycemia). Prolonged hyperglycemia can lead to serious health problems impacting the eyes, major organs, and even cognitive function, which is particularly concerning in developing children," Robert Vigersky, M.D., Chief Medical Officer, Medtronic Diabetes, Professor of Medicine, Uniformed Services University of the Health Sciences "With its responsive algorithm, the MiniMed™ 780G system can help people living with diabetes even when they occasionally forget to bolus or undercount their carbs. The system takes on more of the work involved in diabetes management and helps alleviate mental burden."

"We're incredibly proud that the MiniMed™ 780G system continues to be the most widely used automated insulin delivery system in Europe since we launched it in 2020. Real-world data on over 100,000 users on the system across many geographies and cultures shows that when using recommended settings the system is delivering an average Time in Range of nearly 80%, raising the bar on what 'good' looks like²," said Que Dallara, EVP and President, Medtronic Diabetes. "With the introduction of Simplera Sync™ sensor, we're able to offer the proven benefits of our MiniMed™ 780G system with our newest and most comfortable sensor that can be applied in under 10 seconds."

The MiniMed™ 780G system with Simplera Sync™ sensor is indicated for ages 7+ and compatible with iOS and Android. Simplera Sync™ sensor is not approved by the FDA and is limited to investigational use in the U.S.  

Simplera Sync™ sensor is designed to leverage Medtronic's advanced AID algorithm as part of its MiniMed™ 780G system while having a similar look and feel as the Simplera™ CGM. The Simplera™ CGM for integrated use with the InPen™ smart insulin pen received CE Mark in September 2023.

About the Diabetes Business at Medtronic (www.medtronicdiabetes.com)
Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1. Data on file, CIP330 Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics.
2. Choudhary, Arrieta, van den Heuvel, Castaneda, Smaniotto, Cohen. Celebrating the data from 100,000 real-world users of the MiniMed 780G system in Europe, Middle East and Africa collected over 3 years: from data to clinical evidence. DTT Epub ahead of print. Doi: 10.1089/dia.2023.0433

*Participants in a clinical trial reported the sensor was smaller and lighter than other sensors they have used. Data on file: CIP330, N=243, ages 2-80.
†Refers to auto correct, which provides bolus assistance. Can deliver all correction doses automatically without user interaction, feature can be turned on and off.
‡Taking a bolus 15 – 20 minutes before a meal helps to keep blood sugar levels under control after eating.
§ Refers to SmartGuard™ feature. Individual results may vary.
**A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions. Refer to System User Guide – SmartGuard™ feature. Some user interaction required.

Media Kit: https://news.medtronic.com/MiniMed-TM-780G-System-with-Simplera-Sync-TM

Contacts:
Ashley Patterson	Ryan Weispfenning
Public Relations	Investor Relations
+1-818-576-3025	+1-763-505-4626

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-diabetes-announces-worlds-first-approval-for-minimed-780g-system-with-simplera-sync-disposable-all-in-one-sensor-302027750.html

SOURCE Medtronic plc

FAQ

What is the new product that Medtronic plc (MDT) has received CE Mark approval for?

Medtronic plc (MDT) has received CE Mark approval for the MiniMed™ 780G system with Simplera Sync™ sensor.

What are the key features of the MiniMed™ 780G system with Simplera Sync™ sensor?

The system features a two-step insertion process, automatically adjusts glucose levels, and has a Meal Detection™ feature to reduce post-meal hyperglycemia. It is also compatible with the world's only 7-day infusion set and requires no fingersticks.

When will the MiniMed™ 780G system with Simplera Sync™ sensor be available in Europe?

The system will be available in Europe via limited release in spring 2024, with a phased commercial launch starting in the summer of 2024.

What age group is the MiniMed™ 780G system with Simplera Sync™ sensor indicated for?

The system is indicated for ages 7+ and is compatible with iOS and Android.

What is the purpose of the Simplera Sync™ sensor?

The Simplera Sync™ sensor is designed to leverage Medtronic's advanced AID algorithm as part of its MiniMed™ 780G system while having a similar look and feel as the Simplera™ CGM. It is not approved by the FDA and is limited to investigational use in the U.S.